Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07613684 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants
A Phase 1 study, sponsored by Epirium Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT07613684 is a Phase 1 study that has completed, run by Epirium Bio. The registered enrollment target is 100 participants.
The verdict
NCT07613684, a Phase 1 study, has completed, sponsored by Epirium Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The study will consist of 2 parts, Study Parts 1 (1a: single ascending dose \[SAD\] Phase; and 1b: Food Effect Phase) and Part 2 (multiple ascending dose \[MAD\] Phase). The SAD and MAD phases will evaluate separately non-elderly (≥ 18 to ≤ 65 years of age) and elderly (\> 65 to ≤75 years of age) healthy adult subjects.
Interventions
- DRUG Placebo
- DRUG MF-300 SAD
- DRUG MF-300 Food Effect
- DRUG MF-300 MAD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-12-20 |
| Est. Completion | 2025-10-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07613684
The ClinicalTrials.gov registry entry for NCT07613684 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Epirium Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07613684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07613684 about?
NCT07613684 is a clinical study titled "Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants". The study will consist of 2 parts, Study Parts 1 (1a: single ascending dose \[SAD\] Phase; and 1b: Food Effect Phase) and Part 2 (multiple ascending dose \[MAD\] Phase). The SAD and MAD phases will evaluate separately non-elderly (≥ 18 to ≤ 65 years of age) and elderly (\> 65 to ≤75 years of age) he...
What is the current status of trial NCT07613684?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-12-20. Estimated completion is 2025-10-09.
What interventions are being tested in trial NCT07613684?
The interventions under investigation include: Placebo (DRUG), MF-300 SAD (DRUG), MF-300 Food Effect (DRUG), MF-300 MAD (DRUG).
Who is sponsoring clinical trial NCT07613684?
This trial is sponsored by Epirium Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.